{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:32:27Z","timestamp":1765279947314},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6265","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T22:16:48Z","timestamp":1472681808000},"page":"2359-2364","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Oxidative Stress in Women with Polycystic Ovarian Syndrome as Represented by Serum Ischemia Modified Albumin and Its Correlation with Testosterone and Insulin Resistance"],"prefix":"10.2169","volume":"55","author":[{"given":"Fatma","family":"Beyazit","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Canakkale Onsekiz Mart University, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafiye","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Reproductive Endocrinology and IVF, Dr. Zekai Tahir Burak Women's Health, Education and Research Hospital, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Balci","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Meram Medicine Faculty, Selcuk University, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdi","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Reproductive Endocrinology and IVF, Dr. Zekai Tahir Burak Women's Health, Education and Research Hospital, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selen Taflan","family":"Yaman","sequence":"additional","affiliation":[{"name":"Department of Reproductive Endocrinology and IVF, Dr. Zekai Tahir Burak Women's Health, Education and Research Hospital, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Franks S. Polycystic ovary syndrome. Arch Dis Child 77: 89-90, 1997.","DOI":"10.1136\/adc.77.1.89"},{"key":"2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2006.03061.x","volume":"144","author":"JR Palacio","year":"2006","unstructured":"2. Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Mart\u00ednez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol 144: 217-222, 2006.","journal-title":"Clinical & Experimental Immunology","ISSN":"http:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Dinger Y, Akcay T, Erdem T, Ilker Saygili E, Gundogdu S. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scand J Clin Lab Invest 65: 721-728, 2005.","DOI":"10.1080\/00365510500375263"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Insenser M, Mart\u00ednez-Garc\u00eda MA, Montes R, San-Mill\u00e1n JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. J Clin Endocrinol Metab 95: 3863-3870, 2010.","DOI":"10.1210\/jc.2010-0220"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Poston L, Igosheva N, Mistry HD, et al. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr 94: 1980S-1985S, 2011.","DOI":"10.3945\/ajcn.110.001156"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 49: 177-184, 2011.","DOI":"10.1515\/CCLM.2011.037"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21: 29-34, 2004.","DOI":"10.1136\/emj.2003.006007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 24: 311-317, 2008.","DOI":"10.1155\/2008\/784313"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 95: 586-591, 2010.","DOI":"10.1210\/jc.2009-1592"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Duarte MM, Rocha JB, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 42: 666-671, 2009.","DOI":"10.1016\/j.clinbiochem.2009.01.010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bhakthavatsala Reddy C, Cyriac C, Desle HB. Role of "Ischemia Modified Albumin" (IMA) in acute coronary syndromes. Indian Heart J 66: 656-662, 2014.","DOI":"10.1016\/j.ihj.2014.12.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Guven S, Karahan SC, Bayram C, Ucar U, Ozeren M. Elevated concentrations of serum ischaemia-modified albumin in PCOS, a novel ischaemia marker of coronary artery disease. Reprod Biomed Online 19: 493-500, 2009.","DOI":"10.1016\/j.rbmo.2009.05.012"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47, 2004.","DOI":"10.1093\/humrep\/deh098"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 19: 311-315, 2000.","DOI":"10.1016\/S0736-4679(00)00255-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Caglar GS, Oztas E, Karadag D, Pabuccu R, Demirtas S. Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. Fertil Steril 95: 310-313, 2011.","DOI":"10.1016\/j.fertnstert.2010.06.092"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 24: 333-341, 2009.","DOI":"10.2133\/dmpk.24.333"},{"key":"17","unstructured":"17. Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V. Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 49: 260-266, 2008."},{"key":"18","unstructured":"18. Cakir E, Ozbek M, Ozkaya E, et al. Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients. J Endocrinol Invest 34: e178-e182, 2011."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 30: 45-53, 2006.","DOI":"10.1385\/ENDO:30:1:45"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ali AT. Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol 80: 279-289, 2015.","DOI":"10.1093\/med\/9780190214791.003.0016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 83: 1454-1460, 2005.","DOI":"10.1016\/j.fertnstert.2004.11.070"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Macut D, Simic T, Lissounov A, et al. Insulin resistance in non-obese women with polycystic ovary syndrome: relation to byproducts of oxidative stress. Exp Clin Endocrinol Diabetes 119: 451-455, 2011.","DOI":"10.1055\/s-0031-1279740"},{"key":"23","unstructured":"23. Ciftci CF, Uckuyu A, Karadeli E, Turhan E, Toprak E, Ozcimen EE. Phenotypic subgroups of polycystic ovary syndrome have different intra-renal resistance symptoms. Ginekol Pol 83: 910-915, 2012."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pangaribuan B, Yusuf I, Mansyur M, Wijaya A. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Ther Adv Endocrinol Metab 2: 235-245, 2011.","DOI":"10.1177\/2042018811423770"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Ertekin B, Kocak S, Defne Dundar Z, et al. Diagnostic value of ischemia-modified albumin in acute coronary syndrome and acute ischemic stroke. Pak J Med Sci 29: 1003-1007, 2013.","DOI":"10.12669\/pjms.294.3176"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ma Y, Kang W, Bao Y, Jiao F, Ma Y. Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients. PLoS One 8: e79426, 2013.","DOI":"10.1371\/journal.pone.0079426"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kim JS, Hwang HJ, Ko YG, et al. Ischemia-modified albumin: is it a reliable diagnostic and prognostic marker for myocardial ischemia in real clinical practice? Cardiology 116: 123-129, 2010.","DOI":"10.1159\/000317091"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bhagavan NV, Ha JS, Park JH, et al. Utility of serum Fatty Acid concentrations as a marker for acute myocardial infarction and their potential role in the formation of ischemia-modified albumin: a pilot study. Clin Chem 55: 1588-1590, 2009.","DOI":"10.1373\/clinchem.2008.123315"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 48: 2482-2484, 2006.","DOI":"10.1016\/j.jacc.2006.06.007"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 48: 1097-1100, 2002.","DOI":"10.1093\/clinchem\/48.7.1097"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Reiter RJ, Kaski JC. Association of ischemia-modified albumin and melatonin in patients with ST-elevation myocardial infarction. Atherosclerosis 199: 73-78, 2008.","DOI":"10.1016\/j.atherosclerosis.2007.10.019"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/17\/55_55.6265\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:05Z","timestamp":1601056025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/17\/55_55.6265\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":31,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6265","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}